Dietary Supplements Among Cancer Patients: Tolerance, Impact on Medications, and Potential Drug Interactions
Use of Dietary Supplements Among Cancer Patients: Tolerance and Impact on Medications and Drug Interactions Assessed Using the Hedrine Software
Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI)
1,000 participants
Jun 1, 2025
OBSERVATIONAL
Conditions
Summary
The goal of this observational study is to To assess the prevalence and patterns of dietary supplement use among patients with cancer and to analyze the impact of these supplements in the context of anticancer medical treatments, including chemotherapy, targeted therapies, hormone therapy, and immunotherapies. The main questions it aims to answer : * What is the prevalence of dietary supplement use among cancer patients, and what is their tolerance profile? * Are there any potential drug interactions between dietary supplements and anticancer medications? Participants will: * Provide sociodemographic information, including age, sex, educational level, and other relevant characteristics. * Report their use of dietary supplements, including the types of supplements consumed (e.g., vitamins, minerals, herbal products), dietary practices, frequency and duration of use, and reasons for consumption (e.g., medical recommendation or self-medication). * Report any perceived adverse effects related to dietary supplement use to assess tolerance. * Allow the collection of relevant clinical data from their medical records, including cancer type, ongoing anticancer treatments, and treatment-related adverse effects.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will complete a structured face-to-face questionnaire on dietary supplement use, reasons for Use, frequency and duration of use, perceived adverse effects, and concomitant anticancer treatments.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07670234